ArticleFrontiers in medicine2020
Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 23 citations in OpenAlex.
- Azathioprine as maintenance therapy for IgG4-related diseases: a retrospective case series and case-based review of the literature.Rheumatology international · 2026Review
- Management of IgG4-related cholangitis: diagnosis, therapy, and long-term surveillance.Gastroenterology report · 2025Review
- IgG4-related disease - focus on digestive system involvement.Frontiers in immunology · 2025Review
- Clinical features of immunoglobulin G4-related spinal pachymeningitis.Frontiers in human neuroscience · 2025Article
- Case Report: A rare case of concurrence of IgG4-related tubulointerstitial nephritis and renal Amyloid A amyloidosis.Frontiers in immunology · 2025Article
- Pathogenic roles of follicular helper T cells in IgG4-related disease and implications for potential therapy.Frontiers in immunology · 2024Review
- IgG4-related diseases of the digestive tract.Nature reviews. Gastroenterology & hepatology · 2022Review
- Improved clinical outcomes of tocilizumabTherapeutic advances in chronic disease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.